APA (7th ed.) Citation

Nelson, C. H., Etchevers, K., Yi, S., Breckenridge, D., Hepner, M., Patel, U., . . . Mathias, A. (2020). Pharmacokinetics, Safety, and Tolerability of Selonsertib, an Apoptosis Signal-Regulating Kinase 1 (ASK1) Inhibitor, Following First-in-Human Single and Multiple Ascending Doses in Healthy Subjects. Clinical pharmacokinetics, 59(9), 1109-1117. https://doi.org/10.1007/s40262-020-00878-y

Chicago Style (17th ed.) Citation

Nelson, Cara H., Kim Etchevers, Saili Yi, David Breckenridge, Mischa Hepner, Uptal Patel, John Ling, and Anita Mathias. "Pharmacokinetics, Safety, and Tolerability of Selonsertib, an Apoptosis Signal-Regulating Kinase 1 (ASK1) Inhibitor, Following First-in-Human Single and Multiple Ascending Doses in Healthy Subjects." Clinical Pharmacokinetics 59, no. 9 (2020): 1109-1117. https://doi.org/10.1007/s40262-020-00878-y.

MLA (9th ed.) Citation

Nelson, Cara H., et al. "Pharmacokinetics, Safety, and Tolerability of Selonsertib, an Apoptosis Signal-Regulating Kinase 1 (ASK1) Inhibitor, Following First-in-Human Single and Multiple Ascending Doses in Healthy Subjects." Clinical Pharmacokinetics, vol. 59, no. 9, 2020, pp. 1109-1117, https://doi.org/10.1007/s40262-020-00878-y.